10 December 2025
Efferon LPS® incorporated into clinical guidelines of the German Society of Nephrology for therapeutic apheresis

Efferon LPS has been officially acknowledged in the updated clinical guidelines of the German Society of Nephrology. This inclusion marks a new treatment method for patients with sepsis – “simultaneous hemoadsorption of endotoxins and cytokines”.
The decision to include Efferon LPS® in the treatment protocol is supported by a growing body of clinical data. Updated German guidelines cite a prospective, randomized, controlled study of 58 patients with intra-abdominal sepsis and septic shock. In this study, patients in the Efferon LPS group demonstrated significant and rapid improvements in mean arterial pressure and the Horowitz index, as well as faster weaning from mechanical ventilation compared to standard therapy.
Efferon LPS® is a next-generation extracorporeal blood adsorber, manufactured in the EU with European CE certificate (according to the MDR regulation).
Efferon LPS® is available in more than 35 countries in the world, including Germany as HEMATOPURE DUO by our partner Diamed.
More news
- Efferon®NEO Receives CE MDR Mark22 April 2026
- Efferon at ISICEM10 April 2026
- Efferon first distributors meeting08 April 2026
- Efferon is now available in Poland11 March 2026
- Efferon®LPS is available in Costa Rica26 February 2026
- Efferon®LPS is now approved in Thailand18 February 2026
- We’ll see each other in Greece25 November 2025
- Efferon therapies are now available in Armenia!05 November 2025
- Clinical data confirmed the effectiveness of Efferon NEO in children with sepsis30 October 2025
- Efferon LPS has been approved in the Kingdom of Saudi Arabia.18 October 2025
- Extracorporeal removal of antibiotic drugs during Efferon LPS hemoadsorption is predictable and manageable09 October 2025
- Efferon at the 6th Asia Pacific AKI CRRT Congress in Bangkok05 October 2025
- Win a New iPad! Join the Efferon LPS Photo Challenge on LinkedIn12 September 2025
- Efferon LPS hemoadsorption device has been granted regulatory approval in the United Kingdom and Croatia.23 July 2025
- Efferon LPS Now Available in Italy01 July 2025
- Applying Vicenza’s Lessons28 June 2025
- Efferon Expands Its Global Presence23 June 2025
- Efferon expands to new markets with Bertossi partnership06 June 2025
- Efferon LPS becomes available in Romania.25 May 2025
- New distribution agreements in European countries22 July 2024
- Efferon LPS receives CE mark under EU MDR29 April 2024
- Results of LASSO mRCT are published in Shock20 April 2023
- Efferon at LIVES 2022 in Paris03 November 2022
- Efferon has participated in MEDICA30 November 2021
- LASSO multicenter randomized trial launched29 April 2021